PT  - JOURNAL ARTICLE
AU  - James H. Lillibridge
AU  - Bai Hong Liang
AU  - Bradley M. Kerr
AU  - Stephanie Webber
AU  - Barry Quart
AU  - Bhasker V. Shetty
AU  - Caroline A. Lee
TI  - Characterization of the Selectivity and Mechanism of Human Cytochrome P450 Inhibition by the Human Immunodeficiency Virus-Protease Inhibitor Nelfinavir Mesylate
DP  - 1998 Jul 01
TA  - Drug Metabolism and Disposition
PG  - 609--616
VI  - 26
IP  - 7
4099  - http://dmd.aspetjournals.org/content/26/7/609.short
4100  - http://dmd.aspetjournals.org/content/26/7/609.full
SO  - Drug Metab Dispos1998 Jul 01; 26
AB  - In vitro studies with human liver microsomes and P450 probe substrates were performed to characterize selectivity and mechanism of cytochrome P450 inhibition by nelfinavir mesylate. At therapeutic concentrations (steady-state plasma concentrations ≈4 μM), nelfinavir was found to be a competitive inhibitor of only testosterone 6β-hydroxylase (CYP3A4) with aKi concentration of 4.8 μM. At supratherapeutic concentrations, nelfinavir competitively inhibited dextromethorphan O-demethylase (CYP2D6),S-mephenytoin 4-hydroxylase (CYP2C19), and phenacetinO-deethylase (CYP1A2) with Ki concentrations of 68, 126, and 190 μM, respectively. Nelfinavir did not appreciably inhibit tolbutamide 4-hydroxylase (CYP2C9), paclitaxel 6α-hydroxylase (CYP2C8), or chlorzoxaxone 6β-hydroxylase (CYP2E1) activities. The inhibitory potency of nelfinavir toward CYP3A4 suggested the possibility of in vivo inhibition of this isoform, whereas in vivo inhibition of other P450s was considered unlikely. In a one-sequence crossover study in 12 healthy volunteers, nelfinavir inhibited the elimination of the CYP3A substrate terfenadine and the carboxylate metabolite of terfenadine. The 24-hr urinary recoveries of 6β-hydroxycortisol were reduced by an average of 27% during nelfinavir treatment, consistent with CYP3A inhibition by nelfinavir. Inhibition of CYP3A4 by nelfinavir in vitrowas NADPH-dependent requiring the catalytic formation of a metabolite or a metabolic intermediate. The catechol metabolite of nelfinavir (M3) was considered unlikely to be responsible for inhibition as the addition of catechol O-methyl transferase,S-adenosyl methionine, and ascorbic acid to the preincubation mixture did not protect against the loss of testosterone 6β-hydroxylase activity. Also, the addition of M3 to human liver microsomes did not inhibit CYP3A4. Although incubations with nelfinavir showed a time- and concentration-dependent loss of CYP3A4 activity, the partial or complete recovery of enzyme activity upon dialysis indicated that inhibition was reversible. Microsomal incubations with nelfinavir and NADPH did not result in a loss of spectral P450 content compared with the NADPH control. Glutathione, N-acetylcysteine, and catalase did not attenuate CYP3A4 inhibition by nelfinavir. Collectively, these results suggest that the probable mechanism for CYP3A4 inhibition by nelfinavir is a transient metabolic intermediate or stable metabolite that coordinates tightly but reversibly to the heme moiety of the P450. The American Society for Pharmacology and Experimental Therapeutics